Asma Fatima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Asma Fatima has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Kabir Hassan Biswas
College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar
6 shared publications - Anupriya M. Geethakumari
College of Health & Life Sciences, Hamad Bin Khalifa University, Doha, Qatar
5 shared publications - S. M. Nasir Uddin
College of Health & Life Sciences, Hamad Bin Khalifa University, Doha, Qatar
3 shared publications - Angelin M. Philip
College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar
2 shared publications - Asfia Sultana
College of Health & Life Sciences, Hamad Bin Khalifa University, Doha, Qatar
2 shared publications - Prasanna R. Kolatkar
College of Health and Life Sciences, Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha, Qatar
2 shared publications
Latest Publications
- Open Access
- 26 August 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (10)
A P3′ methionine-to-phenylalanine substitution in the NSP6–7 substrate peptide alters SARS-CoV-2 Mpro dynamics and enhances its processing in living cells
- 26 August 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (10)
Open AccessA P3′ methionine-to-phenylalanine substitution in the NSP6–7 substrate peptide alters SARS-CoV-2 Mpro dynamics and enhances its processing in living cells
- Open Access
- 23 May 2026
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 311, 118848
Differential kinetics of SARS-CoV-2 proteases revealed by a two-color, BRET-based dual protease biosensor, DuProSense
- 23 May 2026
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 311, 118848
Open AccessDifferential kinetics of SARS-CoV-2 proteases revealed by a two-color, BRET-based dual protease biosensor, DuProSense
- Open Access
- 1 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Computational and Structural Biotechnology Journal
- Vol. 35 (1) , 0058
Differential Impact of Substrate Peptides on Interdomain Interactions in Severe Acute Respiratory Syndrome Coronavirus 2 Main Protease
Severe acute respiratory syndrome coronavirus 2 main protease (M pro ) is essential for viral replication by cleaving polyproteins pp1a and pp1ab at 11 sites into functional proteins and remains a major pharmacological target. Although its structure and catalytic mechanism are well characterized, how different substrate peptides dynamically interact with and influence M pro remains incompletely understood. To study these substrate-peptide-specific effects on M pro structural dynamics, we used molecular dynamics (MD) simulations of the M pro dimer bound to its cognate substrate peptides individually and complemented by analyses revealing substrate-peptide-specific structural changes in M pro . Specifically, we generated structural models of all M pro –substrate peptide complexes and performed all-atom, explicit solvent MD simulations. MD trajectory and SHapley Additive exPlanations (SHAP) analyses indicated that substrate peptides modulate M pro dynamics in a substrate-specific manner, predominantly affecting the T45 to M49 and R188 to Q192 residues in the catalytic site. Importantly, this influence does not arise from a single conserved substrate position but from distinct residues across different substrate peptides, highlighting dynamic and context-dependent coupling. Furthermore, hydrogen bond (H-bond) interaction analysis showed substrate-peptide-specific differences in interdomain H-bond interaction between domains I and II. Together, these findings demonstrate that M pro does not respond uniformly to substrate peptide binding; rather, each substrate peptide uniquely reshapes the flexibility of catalytic site residues and interdomain coupling, with potential implications for substrate recognition and inhibitor design.
- 1 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Computational and Structural Biotechnology Journal
- Vol. 35 (1) , 0058
Open AccessDifferential Impact of Substrate Peptides on Interdomain Interactions in Severe Acute Respiratory Syndrome Coronavirus 2 Main Protease
Severe acute respiratory syndrome coronavirus 2 main protease (M pro ) is essential for viral replication by cleaving polyproteins pp1a and pp1ab at 11 sites into functional proteins and remains a major pharmacological target. Although its structure and catalytic mechanism are well characterized, how different substrate peptides dynamically interact with and influence M pro remains incompletely understood. To study these substrate-peptide-specific effects on M pro structural dynamics, we used molecular dynamics (MD) simulations of the M pro dimer bound to its cognate substrate peptides individually and complemented by analyses revealing substrate-peptide-specific structural changes in M pro . Specifically, we generated structural models of all M pro –substrate peptide complexes and performed all-atom, explicit solvent MD simulations. MD trajectory and SHapley Additive exPlanations (SHAP) analyses indicated that substrate peptides modulate M pro dynamics in a substrate-specific manner, predominantly affecting the T45 to M49 and R188 to Q192 residues in the catalytic site. Importantly, this influence does not arise from a single conserved substrate position but from distinct residues across different substrate peptides, highlighting dynamic and context-dependent coupling. Furthermore, hydrogen bond (H-bond) interaction analysis showed substrate-peptide-specific differences in interdomain H-bond interaction between domains I and II. Together, these findings demonstrate that M pro does not respond uniformly to substrate peptide binding; rather, each substrate peptide uniquely reshapes the flexibility of catalytic site residues and interdomain coupling, with potential implications for substrate recognition and inhibitor design.
- 2 February 2026
- Published by Wiley in FEBS Letters
- Vol. 600 (7) , 1101-1113
Ischemic heart disease‐associated ∆ M1 ‐ Q91 PDE5A2 mutant shows reduced efficacy for cGMP , but not sildenafil, binding‐induced conformational change
Phosphodiesterase 5 (PDE5) regulates several physiological processes, including cardiovascular function. A familial PDE5A variant resulting in an N‐terminal truncation (∆M1‐Q91) in PDE5A2 has been linked to premature ischemic heart disease, but its functional impact is unclear. Using computational analysis and BRET‐based biosensors, we show that ∆M1‐Q91 deletion alters structural dynamics and reduces the efficacy of cGMP‐induced conformational change in PDE5. Molecular dynamics simulations and normal mode analysis using structural models revealed altered dynamics and correlated motions in the mutant. BRET assays showed a higher EC 50 for cGMP‐induced, but not sildenafil‐induced, conformational change in the ∆M1‐Q91 mutant PDE5A2. These findings suggest that M1‐Q91 deletion impairs cGMP‐mediated allosteric regulation in PDE5A2 without altering inhibitor sensitivity, offering insights into potential precision therapies targeting this variant.
- 2 February 2026
- Published by Wiley in FEBS Letters
- Vol. 600 (7) , 1101-1113
Ischemic heart disease‐associated ∆ M1 ‐ Q91 PDE5A2 mutant shows reduced efficacy for cGMP , but not sildenafil, binding‐induced conformational change
Phosphodiesterase 5 (PDE5) regulates several physiological processes, including cardiovascular function. A familial PDE5A variant resulting in an N‐terminal truncation (∆M1‐Q91) in PDE5A2 has been linked to premature ischemic heart disease, but its functional impact is unclear. Using computational analysis and BRET‐based biosensors, we show that ∆M1‐Q91 deletion alters structural dynamics and reduces the efficacy of cGMP‐induced conformational change in PDE5. Molecular dynamics simulations and normal mode analysis using structural models revealed altered dynamics and correlated motions in the mutant. BRET assays showed a higher EC 50 for cGMP‐induced, but not sildenafil‐induced, conformational change in the ∆M1‐Q91 mutant PDE5A2. These findings suggest that M1‐Q91 deletion impairs cGMP‐mediated allosteric regulation in PDE5A2 without altering inhibitor sensitivity, offering insights into potential precision therapies targeting this variant.
- Open Access
Differential Kinetics of SARS-CoV-2 Proteases Revealed by a Dual-Color, BRET-based Protease Biosensor, DuProSense
Summary: While SARS-CoV-2 M pro and PL pro proteases are known to cleave polyproteins pp1a and pp1ab at multiple sites, these have not been comprehensively characterized in living cells. Here we engineered a two-color Bioluminescence Resonance Energy Transfer (BRET)-based, dual protease (DuProSense) biosensor platform relying on a proximity-dependent energy transfer from a luciferase donor to two spectrally separated fluorescent protein acceptors enabling simultaneous monitoring of processing of two cleavage sites in a single assay with high specificity. DuProSense revealed a similar M pro and PL pro cleavage kinetics for their N-terminal autocleavage sites. Importantly, systematic characterization of various M pro and PL pro cleavage sites using DuProSense revealed significant differences in cleavage rates and nirmatrelvir potency of M pro cleavage sites but no correlation between the cleavage rates and nirmatrelvir IC 50 values. Overall, our results provide deeper insights into the proteolytic processing of SARS-CoV-2 polyproteins and the dual color BRET platform will find wider applications in the future. Highlights: Engineered a two-color BRET-based, dual protease biosensor (DuProSense) DuProSense biosensor enabled simultaneous and specific monitoring of M pro and PL pro activities DuProSense platform revealed differential cleavage kinetics of M pro cleavage sites in live cells DuProSense platform revealed M pro cleavage site-dependent nirmatrelvir potency in live cells
Open AccessDifferential Kinetics of SARS-CoV-2 Proteases Revealed by a Dual-Color, BRET-based Protease Biosensor, DuProSense
Summary: While SARS-CoV-2 M pro and PL pro proteases are known to cleave polyproteins pp1a and pp1ab at multiple sites, these have not been comprehensively characterized in living cells. Here we engineered a two-color Bioluminescence Resonance Energy Transfer (BRET)-based, dual protease (DuProSense) biosensor platform relying on a proximity-dependent energy transfer from a luciferase donor to two spectrally separated fluorescent protein acceptors enabling simultaneous monitoring of processing of two cleavage sites in a single assay with high specificity. DuProSense revealed a similar M pro and PL pro cleavage kinetics for their N-terminal autocleavage sites. Importantly, systematic characterization of various M pro and PL pro cleavage sites using DuProSense revealed significant differences in cleavage rates and nirmatrelvir potency of M pro cleavage sites but no correlation between the cleavage rates and nirmatrelvir IC 50 values. Overall, our results provide deeper insights into the proteolytic processing of SARS-CoV-2 polyproteins and the dual color BRET platform will find wider applications in the future. Highlights: Engineered a two-color BRET-based, dual protease biosensor (DuProSense) DuProSense biosensor enabled simultaneous and specific monitoring of M pro and PL pro activities DuProSense platform revealed differential cleavage kinetics of M pro cleavage sites in live cells DuProSense platform revealed M pro cleavage site-dependent nirmatrelvir potency in live cells
- Open Access
- 6 September 2024
- Published by Association for Computing Machinery (ACM)
- p. 39-45
Transcriptomic analysis reveals differentially expressed genes and their binding affinity with Gefitinib for lung cancer metastasis
The prevalence of lung cancer is increasing due to different risk factors with lower survival rate. Lung cancer complexity exhibits in its metastasizing ability to brain, bones, and adrenal glands. Therefore, despite the advancement of the field, the entire extent of the genetic variations associated with lung metastasis is still elusive. Patients with lung cancer metastasis show decreased effectiveness or resistance towards the available conventional drugs. In the present article, we used Genomic Data Commons (GDC) to explore the primary lung cancer genes with higher tendency to cause metastasis and aim to investigate the compatible drugs. Based on RNA-seq analysis, TFF2 and REG4 were the top two upregulated differentially expressed genes that we investigated in more details for its affinity with Gefitinib - a first generation FDA approved tyrosine kinase inhibitor drug on these two genes. Molecular docking analysis revealed that these two genes show lower binding affinity to Gefitinib, making it less effective for patients with mutation in these genes compared to patients without mutation. We believe our findings would provide better understanding of the primary mutated genes that could lead to lung cancer metastasizing to other organs and effective drug options in the clinical setting.
- 6 September 2024
- Published by Association for Computing Machinery (ACM)
- p. 39-45
Open AccessTranscriptomic analysis reveals differentially expressed genes and their binding affinity with Gefitinib for lung cancer metastasis
The prevalence of lung cancer is increasing due to different risk factors with lower survival rate. Lung cancer complexity exhibits in its metastasizing ability to brain, bones, and adrenal glands. Therefore, despite the advancement of the field, the entire extent of the genetic variations associated with lung metastasis is still elusive. Patients with lung cancer metastasis show decreased effectiveness or resistance towards the available conventional drugs. In the present article, we used Genomic Data Commons (GDC) to explore the primary lung cancer genes with higher tendency to cause metastasis and aim to investigate the compatible drugs. Based on RNA-seq analysis, TFF2 and REG4 were the top two upregulated differentially expressed genes that we investigated in more details for its affinity with Gefitinib - a first generation FDA approved tyrosine kinase inhibitor drug on these two genes. Molecular docking analysis revealed that these two genes show lower binding affinity to Gefitinib, making it less effective for patients with mutation in these genes compared to patients without mutation. We believe our findings would provide better understanding of the primary mutated genes that could lead to lung cancer metastasizing to other organs and effective drug options in the clinical setting.
- Open Access
- 29 April 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 269, 131864
A slow but steady nanoLuc: R162A mutation results in a decreased, but stable, nanoLuc activity
- 29 April 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 269, 131864
Open AccessA slow but steady nanoLuc: R162A mutation results in a decreased, but stable, nanoLuc activity